Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Increase in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 8,500 shares, an increase of 214.8% from the November 30th total of 2,700 shares. Based on an average trading volume of 898,500 shares, the short-interest ratio is presently 0.0 days.

Provectus Biopharmaceuticals Stock Down 0.4 %

Shares of OTCMKTS PVCT traded down $0.00 during mid-day trading on Friday, hitting $0.12. The company’s stock had a trading volume of 29,945 shares, compared to its average volume of 255,003. Provectus Biopharmaceuticals has a one year low of $0.04 and a one year high of $0.22. The company’s fifty day simple moving average is $0.12 and its 200-day simple moving average is $0.11.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.